This document discusses regulatory issues related to evaluating biotechnology-derived pharmaceuticals. It defines key terms like biopharmaceuticals, biosimilars, and biogenerics. The EU and US have different regulatory approaches and definitions. In India, products are currently referred to as biogenerics and regulated under Schedule Y, though new guidelines are being developed. The presentation outlines important considerations for preclinical safety testing of biologics, including relevant animal species selection, dose levels, routes of administration, and key study types needed like toxicity, immunogenicity, reproductive, and carcinogenicity assessments.
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...Mohamed Fazil M
M. Pharmacy - Pharmaceutical Regulatory Affairs (MRA)
1st Semester - Regulations and Legislation for Biologics (MRA 104T)
Unit 2 - Rules, Regulations, Guidelines and Standards for Regulatory Filing of Biologicals
CDSCO Biologicals
Regulatory requirements for drug approval - industrial pharmacy IIJafarali Masi
Regulatory requirements for drug approval - industrial pharmacy IIDrug Development Teams, Non-Clinical Drug Development, Pharmacology, Drug Metabolism and Toxicology, General considerations of Investigational New Drug (IND) Application, Investigator’s Brochure (IB) and New Drug Application (NDA), Clinical research / BE studies, Clinical Research Protocols, Biostatistics in Pharmaceutical Product Development, Data Presentation for FDA Submissions, Management of Clinical Studies.
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...Mohamed Fazil M
M. Pharmacy - Pharmaceutical Regulatory Affairs (MRA)
1st Semester - Regulations and Legislation for Biologics (MRA 104T)
Unit 2 - Rules, Regulations, Guidelines and Standards for Regulatory Filing of Biologicals
CDSCO Biologicals
Regulatory requirements for drug approval - industrial pharmacy IIJafarali Masi
Regulatory requirements for drug approval - industrial pharmacy IIDrug Development Teams, Non-Clinical Drug Development, Pharmacology, Drug Metabolism and Toxicology, General considerations of Investigational New Drug (IND) Application, Investigator’s Brochure (IB) and New Drug Application (NDA), Clinical research / BE studies, Clinical Research Protocols, Biostatistics in Pharmaceutical Product Development, Data Presentation for FDA Submissions, Management of Clinical Studies.
Looking Beyond Biosimilarity - Importance of Patient Safety: Presentation of...drsomduttprasad
Here is my presentation at FOCUS 2016, the XXIVth Annual Conference of the Bombay Ophthalmologists' Association held from August 19-21, 2016 at ITC Maratha, Hyatt Regency & Hilton, Sahar, Mumbai.
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Biosimilaridad e intercambiabilidad: principios y evidencia: una revisión sis...Rosmirella Cano Rojas
Existen importantes lagunas en la evidencia sobre la seguridad de cambiar entre productos biológicos y sus biosimilares. Se necesitan ensayos clínicos y de farmacovigilancia suficientemente potenciados y adecuadamente analizados estadísticamente , con seguimientos a largo plazo y múltiples cambios, para respaldar la toma de decisiones sobre el cambio biosimilar.
Ich (s5 r2) The International Council for Harmonisationof Technical Requireme...AMIT KUMAR
GUIDLINES FOR REPRODUCTIVE TOXICOLOGY,Strategies for reproductive toxicity assessment,The International Council for Harmonisation,of Technical Requirements for Pharmaceuticals for Human Use
Consideration of ethnic factors during drug approval processSriramNagarajan16
Purpose
To determine feasibility of drug registration for the selected drugs at USFDA based on the ICH E5 guideline.
Methods
Methodology involves two steps, they are 1. Determination of ethnic sensitivity of the selected drugs based on factors
such as pharmacokinetics (PK), pharmacodynamic (PD), therapeutic range, and metabolism etc., given in appendix D
of ICH E5 guidelines. 2. Determination of the need for the bridging studies after determining ethnic sensitivity of the
selected drugs based on the ICH E5 guidelines.
Results
After the extensive analysis of the selected drugs, drugs like nicorandil, may be ethnically insensitive based on ICH
E5 guideline.
Drugs like, nicorandil, may be approved by USFDA without need of bridging studies because they are ethnically
insensitive and medical practice across the ICH countries is mostly similar. The efficacy and safety of these drugs is
demonstrated by the fact that these drugs are on the market for at least 25 years and prescribed in the millions of the
patients.
Conclusion
Nicorandil may be ethnically insensitive among the selected drugs based on the ICH E5 guideline. Drugs like
nicorandil may be approved by USFDA (United States Food and Drug Administration) without need of bridging
studies
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Looking Beyond Biosimilarity - Importance of Patient Safety: Presentation of...drsomduttprasad
Here is my presentation at FOCUS 2016, the XXIVth Annual Conference of the Bombay Ophthalmologists' Association held from August 19-21, 2016 at ITC Maratha, Hyatt Regency & Hilton, Sahar, Mumbai.
Biosimilars are biological generics drugs.They undergo a rigorous evaluation to get approved.How to prove biosimilariy from analytical comparability is explained using a recently approved US FDA bio-similar monoclonal antibody.
Biosimilaridad e intercambiabilidad: principios y evidencia: una revisión sis...Rosmirella Cano Rojas
Existen importantes lagunas en la evidencia sobre la seguridad de cambiar entre productos biológicos y sus biosimilares. Se necesitan ensayos clínicos y de farmacovigilancia suficientemente potenciados y adecuadamente analizados estadísticamente , con seguimientos a largo plazo y múltiples cambios, para respaldar la toma de decisiones sobre el cambio biosimilar.
Ich (s5 r2) The International Council for Harmonisationof Technical Requireme...AMIT KUMAR
GUIDLINES FOR REPRODUCTIVE TOXICOLOGY,Strategies for reproductive toxicity assessment,The International Council for Harmonisation,of Technical Requirements for Pharmaceuticals for Human Use
Consideration of ethnic factors during drug approval processSriramNagarajan16
Purpose
To determine feasibility of drug registration for the selected drugs at USFDA based on the ICH E5 guideline.
Methods
Methodology involves two steps, they are 1. Determination of ethnic sensitivity of the selected drugs based on factors
such as pharmacokinetics (PK), pharmacodynamic (PD), therapeutic range, and metabolism etc., given in appendix D
of ICH E5 guidelines. 2. Determination of the need for the bridging studies after determining ethnic sensitivity of the
selected drugs based on the ICH E5 guidelines.
Results
After the extensive analysis of the selected drugs, drugs like nicorandil, may be ethnically insensitive based on ICH
E5 guideline.
Drugs like, nicorandil, may be approved by USFDA without need of bridging studies because they are ethnically
insensitive and medical practice across the ICH countries is mostly similar. The efficacy and safety of these drugs is
demonstrated by the fact that these drugs are on the market for at least 25 years and prescribed in the millions of the
patients.
Conclusion
Nicorandil may be ethnically insensitive among the selected drugs based on the ICH E5 guideline. Drugs like
nicorandil may be approved by USFDA (United States Food and Drug Administration) without need of bridging
studies
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
Reg.IssuesCRO.tripati.ppt
1. 1/27
Regulatory Issues for CROs
Evaluation of
Biotechnology-Derived
Pharmaceuticals
K.K. Tripathi, PhD
Adviser and Member Secretary, RCGM
Department of Biotechnology
Ministry of S&T, GOI
kkt@dbt.nic.in
The views expressed in this presentation are those of the author and they have nothing to do with the
regulatory authoriries in place and GOI
2. 2/27
Structure of the Presentation
Basics
• Defining Biotech Medicines, Biopharmaceuticals,
Biogenerics & Biosimilars !!!
• EU and USA scenario and perspectives
•Indian Viewpoint
Regulation
• EU and USA
• India
3. 3/27
What are Biopharmaceuticals? Compared to drug
•Biopharma industry-25 yrs old with >350 marketed
products.
•Term widely used but hardly defined by users
•Over 4 million entries on Google search
•Involves use of biotechnology and pharmaceutical
compared to drug
•Antsense oligos, RNAi, synthetic peptides and other
products mimic biopharma as well drug
4. 4/27
Worldwide off Patent Biotech Medicines often
referred as
Generic Biophamaceuticals, (USA)
Biogenerics, (USA)
Follow-on Biologics, (USA)
Biosimilars, (EU) (rDNA & hybridoma derived)
Off Patent Biologicals, (All)
and so on ,,,,,,,,,,,,,,,
Definition is Market and Commerce based
5. 5/27
Biotech medicines often
replace or supplement a
natural protein produced by
the body, satisfying medical
needs previously unmet by
chemical medicines
What Are Biotech Medicines?
•More than 325 million patients worldwide have been
helped by biotech medicines
•More than 50% of medicines in development are
biotech medicines
6. 6/27
EU View: Biosimilars are not generic pharmaceuticals
–Generics are clinically identical to their reference products
–Biosimilars can never be identical to their reference products
Due to the complexity & variability of a biological, the quality
profile is determined by the manufacturing process
–'the product is the process'
Differences in process are inevitable between different
manufacturers
–minor process differences can lead to marked differences in
clinical profile
7. 7/27
Biosimilars are similar, not identical, to original
biotech products
Biosimilars are similar……. ….Not Identical
Different cell lines
Different mfg process
Small differences in substrate and mfg process may affect
patient safety and clinical efficacy of the product
8. 8/27
Impact of small differences among biotech products
on efficacy and safety is unpredictable
Safety and efficacy can differ significantly with small
changes in –protein biophysical characteristics or –
formulation of the drug produc
Long term safety profile of biosimilars has yet to be
established
Prescribers and patients should be aware of this to
ensure appropriate introduction into clinical practice
Need to recognize safety and efficacy issue in both
approval process and introduction into clinical
practice of biosimilars
9. 9/27
INDIAN Scenario
No Biosimilar, only Biogeneric as in USA
No Guidelines
Schedule Y of Drugs and Cosmetics Act
EMEA/ICH Guidelines
More than 20 products approved so far
Guidelines to be put in place soon
10. 10/27
Biogeneric products approved so far in India
Sal No
1
2
3
4
5
6
7
8
9
10
11
12
Molecule
Human insulin
Erythropoietin
Hepatitis B vaccine
Human growth hormone
Interleukin 2
Interleukin 11
Granulocyte Colony
Stimulating Factor
Colony Stimulating Factor
Interferon2Alpha
Interferon 2Beta
Interferons Gamma
Streptokinase
Sal No
13
14
15
16
17
18
19
20
Molecule
Tissue Plasminogen
Activator
Blood factor VIII
Follicle stimulating
hormone
Teriparatide (Forteo)
Drerecogin (Xigris) alpha
Platelet Derived Growth
factor (PDGF)
Epidermal Growth factor
(EGF)
Eptacogalpha (r-F VIIa) r-
coagulation factor
Refer DBT Website: www.igmoris.nic.in
11. 11/27
The Primary Goals of Preclinical
Safety Evaluation are
• Identify an initial safe dose and subsequent
dose escalation schemes in humans
• Identify potential target organs for toxicity and
for reversibility
• Identify safety parameters for clinical
monitoring
12. 12/27
The Test Materials
Monoclonal antibodies, Cytokines, Growth factors,
Vaccines, Fusion proteins, Hormones, Chemically
synthesized peptides, Enzymes, Plasma derived
products, Receptors, Oligonucleotides, proteins
extracted from human tissue, biotransformed drugs
with small molecular weight as generic products of
Pharma, and Guess what more !!!!!!
13. 13/27
The Test Substances
•Investigational new drug or new entities
•Biologically similar to an already tested
and used drug or molecule as a biologic
• What to term it Biogeneric? Biosimilar?
Or !!!!!
14. 14/27
Comparability
Evaluated on the basis of biochemical and
biological characterization (i.e., identity,
purity, stability, and potency).
In some cases, additional studies may be
needed (i.e., pharmacokinetics, pharmaco-
dynamics and / or safety).
15. 15/27
Preclinical Safety Testing
Requirements
Selection of the relevant animal
species;
Age;
Physiological state;
Dose, route of administration, and
treatment regimen; and
Stability of the test material under the
conditions of use.
16. 16/27
Approaches
Conventional approaches to toxicity testing of
pharmaceuticals may not be appropriate due
to the unique and diverse structural and
biological properties.
This includes species specificity,
immunogenicity, and unpredicted activities.
Biological activity may be evaluated using in
vitro assays.
17. 17/27
Receptor / Epitope Distribution
Knowledge of receptor/ epitope distribution can
provide greater understanding of potential in vivo
toxicity .
Relevant animal species for testing of monoclonal
antibodies are those that express the desired epitope
and demonstrate a similar tissue cross-reactivity
profile as for human tissues.
An animal species that does not express the desired
epitope may still be of some relevance for assessing
toxicity if comparable unintentional tissue cross
reactivity to humans is demonstrated.
18. 18/27
Species to be Studied
Safety evaluation programs should normally include
two relevant species.
one relevant species may suffice (e.g., when only
one relevant species can be identified or where the
biological activity of the biopharmaceutical is well
understood).
In addition, even where two species may be
necessary to characterize toxicity in short term
studies, it may be possible to justify the use of only
one species for subsequent long-term toxicity
studies (e.g., if the toxicity profile in the two species
is comparable in the short term).
19. 19/27
When No Relevant
Species Exists
The use of relevant transgenic animals expressing
the human receptor or the use of homologous
proteins should be considered.
Pharmacological mechanism(s) may differ between
the homologous form and the product intended for
clinical use.
Where it is not possible to use transgenic animal
models or homologous proteins evaluation in a
single species, e.g., a repeated dose toxicity study
of < 14 days duration that includes an evaluation of
important functional endpoints (e.g., cardiovascular
and respiratory).
20. 20/27
Administration / Dose Selection
The route and frequency of administration as close as
possible to proposed clinical use.
Pharmacokinetics and bioavailability of the product in the
species being used.
Effects of volume, concentration, formulation, and site of
administration.
The use of routes of administration other than those used
clinically may be acceptable if the route must be modified
due to limited bioavailability, limitations due to the route of
administration, or to size/physiology of the animal species.
Two routes otherwise is not required.
21. 21/27
Dosage levels
Dosage levels should be selected to provide
information on a dose-response relationship,
Include a toxic dose and a no observed adverse
effect level (NOAEL).
Products with little to no toxicity, it may not be
possible to define a specific maximum dose.
In these cases, a scientific justification of the
rationale for the dose selection and projected
multiples of human exposure should be provided.
Where a product has a lower affinity to or potency
in the cells of the selected species than in human
cells, testing of higher doses may be important.
23. 23/27
Carcinogenicity Studies 2
With some biopharmaceuticals, there is a
potential concern about accumulation of
spontaneously mutated cells (e.g., via
facilitating a selective advantage of
proliferation) leading to carcinogenicity.
The standard battery of genotoxicity tests is not
designed to detect these conditions.
Alternative in vitro or in vivo models to address
such concerns may have to be developed and
evaluated.